Hyopthyroidism Treatment in Aging and Thyroid Cancer
衰老和甲状腺癌中的甲状腺功能减退症治疗
基本信息
- 批准号:8318708
- 负责人:
- 金额:$ 36.89万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2010
- 资助国家:美国
- 起止时间:2010-09-01 至 2015-08-31
- 项目状态:已结题
- 来源:
- 关键词:Academic Medical CentersAddressAdultAffectAgeAgingAmericanAmericasAutoimmune ProcessBehaviorBiochemicalBiological AvailabilityBiological MarkersCarbonChronic DiseaseClinicalConsensusDataDetectionDiagnosisDifferentiation and GrowthDiseaseDoseDrug KineticsEffectivenessElderlyEpidemiologic StudiesFerritinFunctional disorderGoalsHealthHealthcare SystemsHormonalHormonesHumanHypothyroidismIndividualIodide PeroxidaseKnowledgeLabelLaboratoriesLiquid ChromatographyMalignant neoplasm of thyroidMeasurementMeasuresMedicalMetabolismMethodsModificationMonitorMoodsMorphologic artifactsOralOutcomePatient RecruitmentsPatientsPeripheralPersonsPharmaceutical PreparationsPopulationPopulation StudyPregnancyPreparationPublic HealthReference ValuesRegimenReplacement TherapyResearchSHBG geneSamplingSerumSurveysSymptomsTechnologyTestingTherapeuticTherapeutic InterventionThyroglobulin antibodyThyroid DiseasesThyroid Function TestsThyroid GlandThyroid HormonesThyrotropinThyroxineTissuesTracerTranslatingUnited StatesWomanage relatedaging populationcomparison groupdesigndiagnosis evaluationexperiencehormone metabolismimprovedinnovationliquid chromatography mass spectrometrymennovelolder patientstemsuccesstandem mass spectrometry
项目摘要
DESCRIPTION (provided by applicant): Thyroid disease represents a significant medical and public health challenge in the United States affecting over 19 million Americans. Hypothyroidism (HT) found in 4.6% of the US population, is increasingly common in the elderly affecting more than 20% of women and 11% of men. Hypothyroidism is defined by an elevated serum thyroid stimulating hormone (TSH) concentration with low serum thyroxine (T4) and tri- iodothyronine (T3) concentrations. Population studies demonstrate an age-related elevation in TSH concentrations, but at present, there is no consensus regarding the TSH concentration at which replacement therapy should be initiated. Another significant gap in knowledge is a lack of pharmacokinetic data of levothyroxine specifically in aging. The presence of endogenous thyroxine makes it impossible to differentiate between internally and externally-derived thyroxine using conventional laboratory tests. In Aims 1 we will conduct pharmacokinetic studies of 13C-LT4 in the elderly. We have designed and validated this method, using state-of- the-art technology, which permit the measurement of exogenous LT4 and conduct pharmacokinetic studies of single dose oral LT4 replacement. A secondary aim (Aim 2) will examine the bioactivity of TSH, assuming the age-related elevation in TSH concentrations consists of relatively more inactive TSH. Aim 3 will examine age-related thyroid hormone activity in peripheral tissues reflecting drug effectiveness. Our experience in patient recruitment and conducting PK studies using state-of-the- art liquid chromatography tandem mass spectrometry (LC/MS/MS) at Georgetown University Medical Center (GUMC), as well as our preliminary data, assure the success of this proposal. If the goals of this research are achieved it will advance the knowledge in the field and have a major impact on the aging population; with the aging of America's baby boomers the need to fully understand the progression thyroid disease, to improve diagnosis and treatment is vitally important to our nation and to our healthcare systems. We believe that these unique and innovative studies will provide a wealth of information that will translate to improved diagnosis, evaluation and management of therapeutic interventions.
PUBLIC HEALTH RELEVANCE: Thyroid disease represents a significant medical and public health challenge in the United States affecting over 19 million Americans. In order to diagnose, treat and manage hypothyroid disease appropriately we need elucidate and characterize the age- associated differences in thyroid hormone metabolism, especially in women. This will help in setting therapeutic goals and help millions in diagnosis, treatment and management of thyroid disease in aging.
描述(由申请人提供):甲状腺疾病是美国一项重大的医疗和公共卫生挑战,影响超过1900万美国人。甲状腺功能减退症(HT)在4.6%的美国人口中发现,在老年人中越来越常见,影响超过20%的女性和11%的男性。甲状腺功能减退症的定义是血清促甲状腺激素(TSH)浓度升高,血清甲状腺素(T4)和三碘甲状腺原氨酸(T3)浓度降低。人群研究表明,TSH浓度与年龄相关,但目前对于应开始替代治疗的TSH浓度尚无共识。 另一个重要的知识缺口是缺乏左旋甲状腺素的药代动力学数据,特别是在老龄化。内源性甲状腺素的存在使得使用常规实验室测试无法区分内部和外部来源的甲状腺素。在目的1中,我们将在老年人中进行13 C-LT 4的药代动力学研究。我们设计并验证了这种方法,使用最先进的技术,允许测量外源性LT 4和进行单剂量口服LT 4替代药代动力学研究。第二个目标(目标2)将检查TSH的生物活性,假设年龄相关的TSH浓度升高由相对更多的无活性TSH组成。目的3将检查反映药物有效性的外周组织中与年龄相关的甲状腺激素活性。 我们在乔治敦大学医学中心(GUMC)使用最先进的液相色谱串联质谱(LC/MS/MS)进行患者招募和PK研究的经验以及我们的初步数据,确保了该提案的成功。如果这项研究的目标得以实现,它将推进该领域的知识,并对老龄化人口产生重大影响;随着美国婴儿潮一代的老龄化,需要充分了解甲状腺疾病的进展,改善诊断和治疗对我们的国家和我们的医疗保健系统至关重要。我们相信,这些独特和创新的研究将提供丰富的信息,将转化为改善诊断,评估和治疗干预的管理。
公共卫生相关性:甲状腺疾病在美国是一个重大的医疗和公共卫生挑战,影响超过1900万美国人。为了正确诊断、治疗和管理甲状腺功能减退症,我们需要阐明和描述甲状腺激素代谢的年龄相关差异,尤其是女性。这将有助于制定治疗目标,并帮助数百万人诊断,治疗和管理老年甲状腺疾病。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Offie P Soldin其他文献
Offie P Soldin的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Offie P Soldin', 18)}}的其他基金
Hyopthyroidism Treatment in Aging and Thyroid Cancer
衰老和甲状腺癌中的甲状腺功能减退症治疗
- 批准号:
8133389 - 财政年份:2010
- 资助金额:
$ 36.89万 - 项目类别:
Hyopthyroidism Treatment in Aging and Thyroid Cancer
衰老和甲状腺癌中的甲状腺功能减退症治疗
- 批准号:
7987882 - 财政年份:2010
- 资助金额:
$ 36.89万 - 项目类别:
TOBACCO SMOKE EXPOSURE AND HORMONAL CHANGES IN WOMEN
女性接触烟草烟雾和荷尔蒙变化
- 批准号:
7608466 - 财政年份:2007
- 资助金额:
$ 36.89万 - 项目类别:
TOBACCO SMOKE EXPOSURE AND HORMONAL CHANGES IN WOMEN
女性接触烟草烟雾和荷尔蒙变化
- 批准号:
7608330 - 财政年份:2006
- 资助金额:
$ 36.89万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 36.89万 - 项目类别:
Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 36.89万 - 项目类别:
Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 36.89万 - 项目类别:
Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 36.89万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 36.89万 - 项目类别:
Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 36.89万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 36.89万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 36.89万 - 项目类别:
EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 36.89万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 36.89万 - 项目类别:
Research Grant